March 19, 2020
Prime showcases how leveraging data, technology and intelligence contains costs and improves the patient experience.
March 18, 2020
This will be the third, high cost drug treatment option emerging for spinal muscular atrophy in less than five years; many more are in the pipeline.
March 13, 2020
This synopsis looks ahead to the new drugs expecting an FDA decision in the month of April.
February 14, 2020
This synopsis looks ahead to the new drugs expecting an FDA decision in the month of March. March 2020 decisions.
February 19, 2020
Prime’s employee volunteers and financial contributions make a difference.
January 15, 2020
A synopsis of the new drugs expecting an FDA decision in the month of February.
January 20, 2020
Trikafka’s triple combination therapy may cover 90% of patients with cystic fibrosis.
January 22, 2020
Ubrelvy™ brings a new treatment option (oral) to a new drug class (CGRP) for patients with migraine. Prime stays on top of the drug pipeline so our clients don’t fall behind.